IFNλ4 Gene Variants Are Associated with CD8+ T Cell IL-2 Response After COVID-19 Vaccination: A Preliminary Study Authors: Giuseppa Luisa Sanfilippo, Giusto Davide Badami, Marco Pio La Manna, Mariangela Pizzo, Domenico Lio, Giovanni Maurizio Giammanco, Nadia Caccamo Published: 2026 ABSTRACT Individual responses to SARS-CoV-2 vaccination vary due to viral mutations, demographic factors, and genetic background, with T-cell responses being less affected by viral variability. However, less is known about the effect of age, sex, and genetic background on the T-cell response in vaccinated subjects. In particular, the influence of interferon lambda (IFN-λ) genetic polymorphisms on vaccine-induced cellular immunity has been poorly explored. Here, we assessed intracellular production of IFNγ, TNFα, and IL-2 in CD4+ and CD8+ T cells stimulated with SARS-CoV-2 spike peptides from 50 vaccinated subjects genotyped for IFNL3 (rs12980275 and rs8099917) and IFNL4 (rs11322783TT and rs12979860) SNPs. We found that the IFNL4 rs11322783TT/TT genotype is associated with increased IL-2 production in CD8+ T cells, whereas the ΔG allele correlates with a reduced IL-2 response. No significant effects on CD4+ T-cell cytokine production or other cytokines were observed. These preliminary findings suggest that type III interferon gene variants might be involved in CD8+ T-cell responses post-vaccination, opening the possibility that evaluation of IFNL4 SNPs might be useful in designing strategies of personalized vaccination. 1. Introduction Vaccines have played a remarkable role in the management and containment of the SARS-CoV-2 pandemic, significantly contributing to reducing the severity of infections [1]. The most widely used formulations contain a modified messenger RNA sequence encoding the virus’s Spike protein [2]. These vaccine formulations induce both antibody and cellular immune responses, with significant involvement of T helper 1 (Th1) and T helper 2 (Th2) and T cytotoxic pathways [3]. On the other hand, a significant component of the antiviral response is the production of IFN-I and IFN-III, in particular against SARS-CoV-infection [4]. IFN-I and IFN-III production is induced by pathogen-associated molecular pattern (PAMP) or damage-associated molecular pattern (DAMP) interaction with pattern recognition receptors, such as TLR molecules (PRRs) [5], expressed in particular on mucosal epithelia [6]. SARS-CoV-2 infection induces IFN-I and IFN-III in different in vitro models: human airway epithelial (HAE) cells, nasal epithelial cells, and immortalized cell lines [7,8]. In vivo, interaction between SARS-CoV-2 and TLR7 receptors activates plasmacytoid dendritic cells (pDCs) in the lung with the production of IFN-α and IFN-λ1, which leads to activation of lung macrophages [9,10]. The same results have been obtained using peripheral blood mononuclear cells as an in vitro model for the immune-cell response to SARS-CoV-2 [10]. So far, four types of interferon III have been identified (IFN-λ1-4) [11]. Unlike type I interferons (such as IFN-α and IFN-β), IFN-λ exerts an antiviral action, mainly localized in the epithelial cells of the mucosal tract, limiting viral infection and systemic inflammation [12]. The central molecular mechanisms of immune-cell activation by IFN-λ are the activation of the Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway by initiating the phosphorylation of JAK1 and tyrosine kinase 2 (TYK2), which subsequently phosphorylate STAT1 and STAT2. Phosphorylated STAT heterodimers binding to cytoplasmic IRF9 form the IFN-stimulated gene factor 3 (ISGF3) complex and, in the nucleus, activate the interferon-stimulated response elements (ISREs) involved in polarization of macrophages and dendritic cells, activation and proliferation of T cells, and, in turn, cytokine gene stimulation [13]. The IFNL3 and IFNL4 genes, encoding, respectively, IFN-λ3 and IFN-λ4, have been widely studied in the past for their role in the clearance of HCV (hepatitis C) virus, but in recent years, attention has been focused on their potential modulatory role in COVID-19 [14,15,16,17,18,19]. In addition, data obtained by different research groups indicate a correlation between IFN-λ levels and COVID-19 severity, with worse effects in low-producing subjects [20,21]. The intensity and effectiveness of the interferon response are influenced by both viral and host factors, with the host’s genetic background playing a significant role [20,21]. Several studies have shown that certain single-nucleotide polymorphisms (SNPs) in type III interferon genes can affect the immune response to SARS-CoV-2 and the clinical outcomes of COVID-19. Among these, rs8099917 and rs12979860 are the most extensively studied, as they influence the expression levels of IFN-λ3 and IFN-λ4, respectively [15,16,17,18,19]. Recent research indicates that individuals carrying the favorable C allele of rs12979860 tend to mount a more effective antiviral response and are at lower risk of severe COVID-19, likely due to enhanced induction of interferon-stimulated genes (ISGs) in the upper airways [17]. In contrast, the TT genotype is associated with a higher risk of severe or fatal COVID-19, possibly due to a weaker and delayed IFN-λ response. Strict genetic control affects IFN-λ4 production. rs11322783 ΔG/TT is characterized by the presence of a G deletion (ancestral ΔG allele) or of an insertion of a TT frameshift. The presence of the ΔG allele is associated with the transcription and synthesis of a functional IFN-λ4 molecule, whereas the presence of the homozygote TT/TT genotype blocks the synthesis of IFN-λ4 [22]. The presence of the IFNL4 rs11322783TT/TT SNPs seems to be associated with a better prognosis of COVID-19 [15,16]. However, less is known about the role that genetic variants of type III interferons (IFN-λ) may play in modulating the efficacy of the immune response induced by SARS-CoV-2 vaccination. In a recent study, we reported that cytokine gene polymorphisms, which are key regulators of inflammation and antibody production, can influence the magnitude of the antibody response to vaccination [23]. Therefore, in this study, we evaluated whether genetic variants in IFN-λ3 and IFN-λ4 are associated with differences in the cellular immune response—specifically, the in vitro response of CD4+ and CD8+ T cells to SARS-CoV-2 spike protein peptides—in vaccinated individuals. 2. Materials and Methods 2.1. Subjects Peripheral blood samples were obtained from 50 healthy subjects (25 males and 25 females, with mean age of 52 years) that received a complete cycle (three or four doses) of the Pfizer/BioNTech BNT162b2 mRNA vaccine. This study was performed according to the Declaration of Helsinki and was approved by the Ethical Committee of A.O.U.P. “P. Giaccone” Hospital (protocol code 09/2021). All participants gave their informed consent, and data were encoded to ensure privacy protection of the subjects. 2.2. Isolation and Culture of Peripheral Blood Mononuclear Cells (PBMCs) Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples using a Ficoll-Paque density gradient (Lympholyte, Cederlane, Burlington, ON, Canada) centrifugation method and promptly stored in liquid nitrogen until use. PBMCs were thawed, resuspended in complete RPMI 1640 medium supplemented with 10% FBS (all from Sigma-Aldrich, Saint Louis, MO, USA) and washed twice. The PBMC viability (>95%) was controlled using Trypan blue staining. PBMCs were cultured with TexMACS™ (Miltenyi Biotec, Bergisch Gladbach, Germany) or RPMI-1640 medium + 5% human serum + BSA/FBS) in 24-well plates at a density of ~400,000 cells/mL. Each sample was cultured in triplicate and stimulated with peptides (Table 1) of the SARS-CoV-2 spike protein (PepTivator® SARS-CoV-2 Prot_S,S1,S+ (Miltenyi Biotec) at a concentration of 0.6 nmol ≈ 1 µg/mL). Negative (containing unstimulated cells) and positive (cells stimulated with CytoStim™ Miltenyi Biotec, a polyclonal TCR/MHC activator at a concentration of 200 µL per ~108 cells) controls were set up for each sample. After 1 h at 37 °C with 5% CO2, 10 µg/mL monensin (BioLegend, Amsterdam, The Netherlands) was added as a Golgi blocker, and plates were incubated for 18–24 h at 3 °C with 5% CO2. 2.3. Flow Cytometry of Peptide-Stimulated Cells After incubation, cells were washed with PBS and stained with the Zombie NIR Fixable Viability kit (BioLegend 423106) to assess cell viability. Cultured cell samples were incubated with anti-CD3, -CD4, and -CD8 REAfinity™ monoclonal antibodies (Miltenyi Biotec); fixed and permeabilized (Inside Stain Kit, Miltenyi Biotec); and subsequently incubated with moAbs specific for TNFα, IFNγ, and IL-2 (Miltenyi Biotec) [24]. Staining was performed using monoclonal antibodies (Miltenyi Biotec), which are recombinant antibodies specifically engineered to eliminate Fc receptor-mediated binding. Consequently, these antibodies do not interact with Fcγ receptors expressed on monocytes, B cells, NK cells, or other immune-cell subsets, thereby minimizing non-specific staining and ensuring high binding specificity. Flow cytometric acquisition of labeled PBMCs was performed using the FACS Lyric flow cytometer (BD Biosciences, San Jose, CA, USA), acquiring a minimum of 200,000 total events for each sample in the lymphocyte gate (based on FSC/SSC). Finally, analysis was performed with FlowJo software v10 (Treestar Inc., Ashland, OR, USA) as previously described [24]. Briefly, gating follows the strategy Live cells →Single events → CD3+ → CD4+/CD8+ → cytokine+ subsets (Figure S1), ensuring reproducibility of the data. A minimum of 50,000 CD3+ cells per sample was required as a quality control (QC) threshold. Results were expressed as the percentage of cytokine-positive CD4+ and CD8+ cells (TNFα+, IFNγ+, or IL-2+) compared with total CD4+ and CD8+ T cells. 2.4. Cytokine SNP Typing Blood samples, in tripotassium EDTA sterile tubes, were used for DNA extraction (“Magna Pure” 24 System automated extraction method; Roche Diagnostics S.p.A., Monza (MB), Italy). As reported in Table 2, we selected seven functional and common SNPs of the IFNG, TNFA, IL2, IFNL3 and IFNL4 genes (http://www.ensembl.org/index.html, last accessed on 18 December 2025). DNA samples were typed as previously described [23] by using the KASPar assay (K-Bioscience Ltd. Hoddesdon, UK). Genotypes analysis was performed on 7300 system SDS software, version 1.3 (Applera Italia, Monza (MI), Italy), as previously described. 2.5. Statistics Mean ± standard deviation and the median of the continuous variables (age, percentage of cells positive for cytoplasmic cytokines and percentage of the increase in intra-cytoplasmic cytokine production) were calculated, and modal distribution was verified by the Kolmogorov and Smirnov method and analysis of variance. When data did not follow a normal distribution model, the non-parametric Mann–Whitney test was applied. To analyze the data, we stratified the subjects into two subsets: subjects that had a percentage of increase in intra-cytoplasmic cytokine production under the median values and subjects with a percentage of increase in cytokine production equal to or greater than the median. We analyzed contingency tables containing the following categories: subjects positive for a genotype and with a cytokine production increase percentage < median (A); genotype-negative and increase